While PGC1α itself is likely not suitable for pharmacological targeting, its downstream effectors may be; inhibiting a crucial factor therein might conceivably render the cancer cell unable to modulate its metabolism and thereby sensitize it to other treatment. This evidence concerns the gene PPARGC1A and cancer.